{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:46:19Z","timestamp":1773413179448,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.heliyon.2023.e15813","type":"journal-article","created":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T01:12:47Z","timestamp":1682817167000},"page":"e15813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review"],"prefix":"10.1016","volume":"9","author":[{"given":"Kangxin","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenhao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huailan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2023.e15813_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupret","year":"2021","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e15813_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J. Urol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15813_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2009.12.001","article-title":"Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study","volume":"57","author":"Lughezzani","year":"2010","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15813_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.euf.2022.11.016","article-title":"Oncologic and safety outcomes for endoscopic surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: an updated systematic review and meta-analysis","volume":"9","author":"Kawada","year":"2023","journal-title":"Eur Urol Focus."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15813_bib5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2023.e15813_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S225301","article-title":"Optimal management of upper tract urothelial carcinoma: current perspectives","volume":"13","author":"Leow","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e15813_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004427","article-title":"Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e15813_bib8","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2023.e15813_bib9","first-page":"1","article-title":"Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond","author":"Bianchi","year":"2022","journal-title":"Expet Opin. Pharmacother."},{"issue":"10232","key":"10.1016\/j.heliyon.2023.e15813_bib10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0140-6736(20)30519-5","article-title":"Treatment of upper urinary tract urothelial carcinoma","volume":"395","author":"Crabb","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e15813_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00345-020-03502-7","article-title":"Immune checkpoint inhibition in upper tract urothelial carcinoma","volume":"39","author":"Califano","year":"2020","journal-title":"World J. Urol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e15813_bib12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15813_bib13","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.21037\/tau-21-268","article-title":"Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report","volume":"10","author":"Ni","year":"2021","journal-title":"Transl. Androl. Urol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15813_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/bju.15324","article-title":"Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes","volume":"128","author":"Esagian","year":"2021","journal-title":"BJU Int."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e15813_bib15","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdz214","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive\/Advanced Cancer of the Urothelium (RISC)","volume":"30","author":"Bamias","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15813_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e15813_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","article-title":"A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now","volume":"54","author":"Bellmunt","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.heliyon.2023.e15813_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e15813_bib19","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15813_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-018-0314-1","article-title":"Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond","volume":"6","author":"Zhu","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"13","key":"10.1016\/j.heliyon.2023.e15813_bib21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e15813_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15813_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e15813_bib24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15813_bib25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jamaoncol.2017.5440","article-title":"Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study","volume":"4","author":"Petrylak","year":"2018","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e15813_bib26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e15813_bib27","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e15813_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10064","key":"10.1016\/j.heliyon.2023.e15813_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"10031","key":"10.1016\/j.heliyon.2023.e15813_bib30","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"10236","key":"10.1016\/j.heliyon.2023.e15813_bib31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"10122","key":"10.1016\/j.heliyon.2023.e15813_bib32","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15813_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e15813_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e15813_bib35","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.heliyon.2023.e15813_bib36","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e15813_bib37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023030207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023030207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:17:56Z","timestamp":1773397076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023030207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2405844023030207"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15813","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15813","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e15813"}}